Stockreport

LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials [Yahoo! Finance]

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Bio [Read more]